Siludi Pharmaceutical Co., Ltd. (01244) achieved revenue of about 211 million yuan in the first half of the year and fully launched a global commercial layout

According to the Zhitong Finance App, Siludi Pharmaceutical Co., Ltd. (01244) announced its 2026 interim results, with revenue of about 211 million yuan, an increase of 0.65% over the previous year; gross profit of about 193 million yuan. R&D expenditure was 63.338 million yuan, a year-on-year decrease of 23.8%. The owner of the parent company should have accounted for a loss of 852.29 million yuan, a year-on-year decrease of 4.61%.

During the reporting period, the group adhered to the pipeline focus strategy, steadily promoted commercial operations, key clinical development and global BD layout, and implemented refined cost and cash flow management to ensure the implementation of the core strategy.

In terms of commercial operation, the Group owns Envida®, a PD-L1 inhibitor that has already been commercialized. As the world's first subcutaneous PD-L1 injection, it has outstanding dosage differentiation advantages, can be adapted to a wide range of combined drug treatment scenarios, and helps continue to repair commercial performance. The development of a number of new indications for Envida® is progressing in an orderly manner: the marketing application for new indications in combination with gemcitabine and oxaliplatin (GEMOX) for first-line biliary cancer was accepted by the NMPA in January 2026, and verification was completed. The complete clinical data for the critical phase III Chinese population was announced at the 2026 ASCO annual meeting; the phase III study for perioperative treatment of non-small cell lung cancer was enrolled during the reporting period, awaiting clinical endpoints; msi-HMMR/MDMMR indications A supplementary application for general approval has also been submitted It was also accepted.

At the level of R&D innovation, the Group relies on years of experience in oncology drug research and development to achieve capacity transfer and collaborative empowerment between technology platforms. Based on long-term research experience accumulated in the PSMA target direction, RDC nuclear drug pipeline development was quickly implemented; relied on years of tumor vaccine research and development to accelerate the construction of an mRNA technology platform; at the same time, AI technology was introduced to enable the entire R&D process, efficiently open up a closed loop of dry and wet experiments, and lay out a number of global patents for LNP delivery systems with differentiated targeting characteristics to consolidate the underlying technical barriers of self-development. As of the first half of 2026, the core asset of the 3D189 (WT1 tumor vaccine) MRCT study, 78 cases have occurred, and the final analysis will be triggered after 80 deaths have occurred. Multiple cutting-edge pipelines such as RDC, mRNA, and in vivo CAR-T continue to advance pre-clinical and early clinical development. A number of core research results were successfully disclosed at the 2026 AACR annual meeting, and the potential for differentiation between platform technology and drug candidates continues to be verified.

In terms of globalization and business development (BD) strategy, the Group adheres to a hierarchical rights operation strategy based in China and facing the world. Mature products give priority to releasing non-core overseas market value and retaining high-value core market interests; late-stage and cutting-edge pipelines simultaneously evaluate global multi-center clinical and diversified cooperation opportunities, and achieve global implementation of innovative value through BD cooperation. Enveda® and Glenmark's overseas licensing projects continue to advance; the Group BD team continues to carry out technical and business exchanges with the global industry, and actively explores various cooperation possibilities such as licensing and joint development.